Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Inês Ribeiro, Francisco Batel Marques, Diogo Mendes & Carlos Alves. (2020) A Systematic Review of Economic Studies Evaluating Ophthalmic Drugs: An Analysis of the Health-state Utilities. Ophthalmic Epidemiology 27:5, pages 325-338.
Read now
Read now
Hammouda Hamdy Ghoraba, Mahmoud Leila, Sameh Mohamed Elgouhary, Emad Eldin Mohamed Elgemai, Haithem Mamon Abdelfattah, Hashem Hammouda Ghoraba & Mohamed Amin Heikal. (2018) Safety of high-dose intravitreal triamcinolone acetonide as low-cost alternative to anti-vascular endothelial growth factor agents in lower-middle-income countries. Clinical Ophthalmology 12, pages 2383-2391.
Read now
Read now
Jennifer Haig, Martin Barbeau & Alberto Ferreira. (2016) Cost-effectiveness of ranibizumab in the treatment of visual impairment due to diabetic macular edema. Journal of Medical Economics 19:7, pages 663-671.
Read now
Read now
Articles from other publishers (17)
Silvia NW Hertzberg, Morten Carstens Moe, Øystein Kalsnes Jørstad, Beáta Éva Petrovski, Emily Burger & Goran Petrovski. (2022) Healthcare expenditure of intravitreal anti‐vascular endothelial growth factor inhibitors compared with dexamethasone implant for diabetic macular oedema. Acta Ophthalmologica 100:8.
Crossref
Crossref
Justin S YuRashad CarltonNeetu AgashivalaTarek HassanCharles C Wykoff. (2021) Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis. Journal of Managed Care & Specialty Pharmacy 27:6, pages 743-752.
Crossref
Crossref
Faris El-Dahiyat & Islam Eljilany. (2020) Cost-Minimization Analysis of Ranibizumab Versus Aflibercept for Treating Saudi Patients With Visual Impairment Owing to Age-Related Macular Degeneration or Diabetic Macular Edema. Value in Health Regional Issues 22, pages 23-26.
Crossref
Crossref
Jian Ming, Yabing Zhang, Xun Xu, Mingwei Zhao, Yusheng Wang, Youxin Chen, Feng Zhang, Jiawei Wang, Jun Liu, Xinran Zhao, Rong Han & Shanlian Hu. (2020) Cost–effectiveness analysis of intravitreal aflibercept in the treatment of diabetic macular edema in China. Journal of Comparative Effectiveness Research 9:3, pages 161-175.
Crossref
Crossref
Michal Pochopien, Annette Beiderbeck, Phil McEwan, Richard Zur, Mondher Toumi & Samuel Aballéa. (2019) Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies. BMC Health Services Research 19:1.
Crossref
Crossref
Nikolaos Maniadakis & Evgenia Konstantakopoulou. (2019) Cost Effectiveness of Treatments for Diabetic Retinopathy: A Systematic Literature Review. PharmacoEconomics 37:8, pages 995-1010.
Crossref
Crossref
Luis HernandezTereza LanitisClifford CeleHector Toro-DiazAndrea GibsonAndreas Kuznik. (2018) Intravitreal Aflibercept Versus Ranibizumab for Wet Age-Related Macular Degeneration: A Cost-Effectiveness Analysis. Journal of Managed Care & Specialty Pharmacy 24:7, pages 608-616.
Crossref
Crossref
Emanuela Foglia, Lucrezia Ferrario, Francesco Bandello, Camilla Ferri, Innocente Figini, Michela Franzin, Gianpiera Gambaro, Ugo Introini, Massimo Medaglia, Giovanni Staurenghi, Patrizia Tadini, Andrea Fomiatti & Davide Croce. (2018) Diabetic macular edema, innovative technologies and economic impact: New opportunities for the Lombardy Region healthcare system?. Acta Ophthalmologica 96:4, pages e468-e474.
Crossref
Crossref
Luis HernandezTereza LanitisClifford CeleHector Toro-DiazAndrea GibsonAndreas Kuznik. (2018) Intravitreal Aflibercept Versus Ranibizumab for Wet Age-Related Macular Degeneration: A Cost-effectiveness Analysis. Journal of Managed Care & Specialty Pharmacy, pages 1-9.
Crossref
Crossref
Oluwaranti Akiyode, Jateh Major & Abiola Ojo. (2016) Aflibercept: A Review of Its Use in the Management of Diabetic Eye Complications. Journal of Pharmacy Practice 30:5, pages 534-540.
Crossref
Crossref
Michael W. StewartMichael W. Stewart. 2017. Diabetic Retinopathy. Diabetic Retinopathy
257
268
.
Georgia Kourlaba, John Relakis, Ronan Mahon, Maria Kalogeropoulou, Georgia Pantelopoulou, Olga Kousidou & Nikos Maniadakis. (2016) Cost-utility of ranibizumab versus aflibercept for treating Greek patients with visual impairment due to diabetic macular edema. Cost Effectiveness and Resource Allocation 14:1.
Crossref
Crossref
M Ashraf, A Souka, R Adelman & S H Forster. (2016) Aflibercept in diabetic macular edema: evaluating efficacy as a primary and secondary therapeutic option. Eye 30:12, pages 1531-1541.
Crossref
Crossref
Wrik Ghosh, Rose Wickstead, Lindsay Claxton, Jeanette Kusel, Matthew Taylor, Kelly Fleetwood & Ruth Pulikottil-Jacob. (2016) The Cost-Effectiveness of Ranibizumab Treat and Extend Regimen Versus Aflibercept in the UK. Advances in Therapy 33:9, pages 1660-1676.
Crossref
Crossref
Tien Y. Wong, Chui Ming Gemmy Cheung, Michael Larsen, Sanjay Sharma & Rafael Simó. (2016) Diabetic retinopathy. Nature Reviews Disease Primers 2:1.
Crossref
Crossref
Oluwaranti Akiyode & Nikeshia Dunkelly-Allen. (2015) Ranibizumab. Journal of Pharmacy Technology 32:1, pages 22-28.
Crossref
Crossref
Lola Adedokun & Colin Burke. (2016) Cost-Effectiveness of Ranibizumab Versus Aflibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion: A UK Healthcare Perspective. Advances in Therapy 33:1, pages 116-128.
Crossref
Crossref